Physician profile
John Amatruda
NPI 1164569224
$319,731.39
in general payments reported to CMS, 2019-2025
6 companies · $119 in 2025
The $119 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $70K · 2020: $53K · 2021: $77K · 2022: $97K · 2023: $23K · 2025: $119.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $23K · Food and Beverage: $119.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $23,380.02 |
| Food and Beverage | $119.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $275,902.75 | 2019-2023 | |
| Ferring Research Institute INC. | $33,215.29 | 2019 | |
| Ferring International Pharmascience Center US | $7,450.00 | 2020 | |
| Genentech, INC. | $3,000.00 | 2019 | |
| Merck Sharp & Dohme LLC | $119.14 | 2025 | |
| Ferring Pharmaceuticals INC. | $44.21 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Amatruda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.